Poniard's Cancer Treatment Disappoints
Shares of Poniard Pharmaceuticals Inc. (Nasdaq: PARD) collapsed $5.86 to $1.73 after the company reported disappointing late-stage results for its cancer drug candidate.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.